Pathophysiology of the metabolic syndrome;Patofiziologija metaboličkog sindroma

Medicus

Volumn 13, Issue 2, 2004, Pages 151-161

  Smirčić Duvnjak, Lea ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Hyperinsulinemia; Insulin; Insulin receptor; Insulin resistance; Visceral adiposity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE TRANSPORTER; INSULIN RECEPTOR; INSULIN RECEPTOR ANTIBODY; INTERLEUKIN 6; LEPTIN; MUTANT PROTEIN; RESISTIN; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL GROWTH; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENETIC DISORDER; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HYPERINSULINEMIA; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET CELL; PROTEIN METABOLISM; REVIEW; THROMBOSIS;

EID: 33645241809     PISSN: 1330013X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. REAVEN GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
2. REAVEN GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-86.
3. REAVEN GM. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: syndrome X revisited. U: Jefferson LS, Cherrington AD, (ur.) Handbook of Physiology. Section 7: The Endocrine System. Volume II: The Endocrine Pancreas and Regulation of Metabolism. New York, NY: Oxford University Press, 2001:1169-97.
4. REAVEN GM. Insulin resistance and its consequences. U: LeRoith D, Taylor SI, Olefasky JM, (ur.) Diabetes Mellitus: A fundamental and clinical text. 3. izd. Philadelphia: Lippincott, Williams and Wilkins, 2004, p. 899-915.
5. SHIRAI K. Obesity as the Core of the Metabolic Syndrome and the Management of Coronary Heart Disease Curr Med Res Opin 2004;20(3):295-304.
6. NESTO RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Mrd 2003;4(6):S11-S18.
7. FLAKOLL PJ, JENSEN MD, CHERRINGTON AD. Physiological action of insulin. U: LeRoith D, Taylor SI, Olefasky JM, (ur.) Diabetes Mellitus: A fundamental and clinical text. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 2004, p. 165-81.
8. LOW WANG C, GOALSTONE ML, DRAZNIN B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004;53(11):2735-40.
9. SIVITZ WI. Liptoxicity and glucotoxicity in type 2 diabetes: effects on development and progression. Postgrad Med 2001;109(4):55-64.
10. SHULMAN GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106(2):171-6.
11. GOLDSTEIN BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90(Suppl 5A):3G-10G.
12. HILLS SA, BALKAU B, COPPACK SW i sur. The EGIRRISC study (the european group for the study of insulin resistance:relationship between insulin sensitivity and cardiovascular disease risk). I: methodology and objectives. Diabetologia 2004;47(3):566-70.
13. DEFRONZO RA, FERRANNINI E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab Care 1991;14:173-94.
14. SOWERS JR, FRONLICH ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004;88:63-82.
15. MEDINA J, FERNANDEZ-SALAZAR LI, GARCIA-BUEY L, MORENO-OTERO R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diab Care 2004;27:2057-66.
16. TSILCHOROZIDOU T, OVERTON C, CONWAY GS. The Pathophysiology of Polycystic Ovary Syndrome. Clin Endocrinol 2004;60(1):1-17.
17. CERIELLO A, MOTZ E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited Arterioscler Thromb Vasc Biol 2004;24:816-23.
18. MEIGS JB i sur. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study. JAMA 2000;283:221-8.
19. PATERSON JM. Metabolic syndrome without obesity: Hepatic overex pression of 11b-hydroxyesteroid dehydrogenase type 1 in transgenic mice. PNAS 2004; 101:7088-93.
20. DESPRES JP. Health consequences of visceral adiposity. Ann Med 2001;33:534-41.